Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 1 (2022)
Review paper
Submitted: 2021-07-06
Accepted: 2021-08-06
Published online: 2021-10-06
View PDF Download PDF file
Get Citation

The outstanding beneficial roles of irisin disorders

Saadet Ilcın1, Sermın Algül1, Oguz Ozcelık2
DOI: 10.5603/EP.a2021.0088
·
Pubmed: 34647610
·
Endokrynol Pol 2022;73(1):149-156.
Affiliations
  1. Department of Physiology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Türkiye
  2. Department of Physiology, Faculty of Medicine, Kastamonu University, Kastamonu, Türkiye

open access

Vol 73, No 1 (2022)
Review Article
Submitted: 2021-07-06
Accepted: 2021-08-06
Published online: 2021-10-06

Abstract

Depression is a widely observed psychiatric disorder that affects a quite large number of people all around the world. A major depressive disorder (MDD) is a multifactorial disease that IS associated with fluctuations in appetite, body weight, and energy situations in addition to serious mood problems. The aim of this review is to investigate a possible link between energy regulatory hormones of irisin and depressive disorders.

Irisin is a hormone that plays a significant role in the regulation of lipid and glucose metabolism in skeletal muscle and adipose tissue. Irisin was also reported to play significant roles in the central nervous system. In the literature there are reports indicating a beneficial antidepressant role of irisin in MDD.

It should be emphasised that the antidepressive effects of exercise could be the result of exercise-induced increased hormones of irisin.

Abstract

Depression is a widely observed psychiatric disorder that affects a quite large number of people all around the world. A major depressive disorder (MDD) is a multifactorial disease that IS associated with fluctuations in appetite, body weight, and energy situations in addition to serious mood problems. The aim of this review is to investigate a possible link between energy regulatory hormones of irisin and depressive disorders.

Irisin is a hormone that plays a significant role in the regulation of lipid and glucose metabolism in skeletal muscle and adipose tissue. Irisin was also reported to play significant roles in the central nervous system. In the literature there are reports indicating a beneficial antidepressant role of irisin in MDD.

It should be emphasised that the antidepressive effects of exercise could be the result of exercise-induced increased hormones of irisin.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

irisin; major depressive disorders; FNDC5; type 2 diabetes mellitus; obesity

About this article
Title

The outstanding beneficial roles of irisin disorders

Journal

Endokrynologia Polska

Issue

Vol 73, No 1 (2022)

Article type

Review paper

Pages

149-156

Published online

2021-10-06

Page views

6707

Article views/downloads

821

DOI

10.5603/EP.a2021.0088

Pubmed

34647610

Bibliographic record

Endokrynol Pol 2022;73(1):149-156.

Keywords

irisin
major depressive disorders
FNDC5
type 2 diabetes mellitus
obesity

Authors

Saadet Ilcın
Sermın Algül
Oguz Ozcelık

References (89)
  1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008; 358(1): 55–68.
    CrossRefPubMed
  2. DSM-IV-TR A. American Psychiatric Association . DSM-IV-TR A. Diagnostic and statistical manual of mental disorders. APA, Washington, DC 2000.
  3. Malhi G, Mann J. Depression. Lancet. 2018; 392(10161): 2299–2312.
    CrossRefPubMed
  4. Ozamiz-Etxebarria N, Dosil-Santamaria M, Picaza-Gorrochategui M, et al. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. Cad Saude Publica. 2020; 36: 00054020.
  5. Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020; 66(5): 504–511.
    CrossRefPubMed
  6. Torales J, O'Higgins M, Castaldelli-Maia JM, et al. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 2020; 66(4): 317–320.
    CrossRefPubMed
  7. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020; 89: 531–542.
    CrossRefPubMed
  8. Algul S, Ozcelik O. Evaluating the Levels of Nesfatin-1 and Ghrelin Hormones in Patients with Moderate and Severe Major Depressive Disorders. Psychiatry Investig. 2018; 15(2): 214–218.
    CrossRefPubMed
  9. Kim S, Choi JY, Moon S, et al. Roles of myokines in exercise-induced improvement of neuropsychiatric function. Pflugers Arch. 2019; 471(3): 491–505.
    CrossRefPubMed
  10. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463–468.
    CrossRefPubMed
  11. Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn. 2002; 224(2): 154–167.
    CrossRefPubMed
  12. Teufel A, Malik N, Mukhopadhyay M, et al. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene. 2002; 297(1-2): 79–83.
    CrossRefPubMed
  13. Erickson HP. Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte. 2013; 2(4): 289–293.
    CrossRefPubMed
  14. Schumacher MA, Chinnam N, Ohashi T, et al. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: implications for receptor activation. J Biol Chem. 2013; 288(47): 33738–33744.
    CrossRefPubMed
  15. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725–1738.
    CrossRefPubMed
  16. Piya MK, Harte AL, Sivakumar K, et al. The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab. 2014; 306(5): E512–E518.
    CrossRefPubMed
  17. Dun SL, Lyu RM, Chen YH, et al. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience. 2013; 240: 155–162.
    CrossRefPubMed
  18. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18(5): 649–659.
    CrossRefPubMed
  19. Xu B. BDNF (I)rising from exercise. Cell Metab. 2013; 18(5): 612–614.
    CrossRefPubMed
  20. Park H, Popescu A, Poo Mm. Essential role of presynaptic NMDA receptors in activity-dependent BDNF secretion and corticostriatal LTP. Neuron. 2014; 84(5): 1009–1022.
    CrossRefPubMed
  21. Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011; 77(3): 288–294.
    CrossRefPubMed
  22. Arida RM, Cavalheiro EA, da Silva AC, et al. Physical activity and epilepsy: proven and predicted benefits. Sports Med. 2008; 38(7): 607–615.
    CrossRefPubMed
  23. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007; 30(9): 464–472.
    CrossRefPubMed
  24. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology. 1999; 21(5): 679–682.
    CrossRefPubMed
  25. Zhang H, Lee JY, Borlongan CV, et al. A brief physical activity protects against ischemic stroke. Brain Circ. 2019; 5(3): 112–118.
    CrossRefPubMed
  26. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98(4): E769–E778.
    CrossRefPubMed
  27. Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013; 8(4): e60563.
    CrossRefPubMed
  28. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6): 324–337.
    CrossRefPubMed
  29. Algul S, Ozdenk C, Ozcelik O. Variations in leptin, nesfatin-1 and irisin levels induced by aerobic exercise in young trained and untrained male subjects. Biol Sport. 2017; 34(4): 339–344.
    CrossRefPubMed
  30. Ozcelik O, Algul S, Yilmaz B. Nesfatin-1 and irisin levels in response to the soccer matches performed in morning, afternoon and at night in young trained male subjects. Cell Mol Biol (Noisy-le-grand). 2018; 64(10): 130–133.
    PubMed
  31. Brown HE, Pearson N, Braithwaite RE, et al. Physical activity interventions and depression in children and adolescents : a systematic review and meta-analysis. Sports Med. 2013; 43(3): 195–206.
    CrossRefPubMed
  32. Gordon BR, McDowell CP, Hallgren M, et al. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms: Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018; 75(6): 566–576.
    CrossRefPubMed
  33. Lee P, Linderman JD, Smith S, et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014; 19(2): 302–309.
    CrossRefPubMed
  34. Phillips C, Baktir MA, Srivatsan M, et al. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front Cell Neurosci. 2014; 8: 170.
    CrossRefPubMed
  35. Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta. 2015; 1852(9): 1867–1875.
    CrossRefPubMed
  36. Rosell M, Kaforou M, Frontini A, et al. Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice. Am J Physiol Endocrinol Metab. 2014; 306(8): E945–E964.
    CrossRefPubMed
  37. Cannon B, Nedergaard J, Zhao J, et al. Coexisting beta-adrenoceptor subtypes: significance for thermogenic process in brown fat cells. Am J Physiol. 1994; 267(4 Pt 1): C969–C979.
    CrossRefPubMed
  38. DAVIS TR, DAVIS TR. Chamber cold acclimatization in man. Rep US Army Med Res Lab. 1961; 475: 1–8.
    PubMed
  39. Li F, Li Y, Duan Y, et al. Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue. Cytokine Growth Factor Rev. 2017; 33: 73–82.
    CrossRefPubMed
  40. Steiner JL, Murphy EA, McClellan JL, et al. Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol (1985). 2011; 111(4): 1066–1071.
    CrossRefPubMed
  41. Zsuga J, Biro K, Papp C, et al. The "proactive" model of learning: Integrative framework for model-free and model-based reinforcement learning utilizing the associative learning-based proactive brain concept. Behav Neurosci. 2016; 130(1): 6–18.
    CrossRefPubMed
  42. Schott BH, Minuzzi L, Krebs RM, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci. 2008; 28(52): 14311–14319.
    CrossRefPubMed
  43. Leyton M. The neurobiology of desire: Dopamine and the regulation of mood and motivational states in humans. In: Kringelbach ML, Berridge KC. ed. Pleasures of the brain. Oxford University Press, Oxford 2010: 222–243.
  44. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 1995; 38(2): 95–137.
    CrossRefPubMed
  45. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006; 30(2): 215–238.
    CrossRefPubMed
  46. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350(6315): 230–232.
    CrossRefPubMed
  47. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59(12): 1151–1159.
    CrossRefPubMed
  48. Walsh JJ, Friedman AK, Sun H, et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. Nat Neurosci. 2014; 17(1): 27–29.
    CrossRefPubMed
  49. Cabib S, Puglisi-Allegra S, Imperato A, et al. Genotype-dependent adaptation of mesolimbic dopamine system and stress-induced behavioral sensitization to amphetamine. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A(1-2): 251A–252A.
    CrossRefPubMed
  50. Mucher P, Batmyagmar D, Perkmann T, et al. Basal myokine levels are associated with quality of life and depressed mood in older adults. Psychophysiology. 2021; 58(5): e13799.
    CrossRefPubMed
  51. Hofmann T, Elbelt U, Ahnis A, et al. The exercise induced myokine irisin does not show an association with depressiveness, anxiety and perceived stress in obese women. J Physiol Pharmacol. 2016; 67: 195–203.
    PubMed
  52. Opmeer EM, Kortekaas R, Aleman A. Depression and the role of genes involved in dopamine metabolism and signalling. Prog Neurobiol. 2010; 92(2): 112–133.
    CrossRefPubMed
  53. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014; 140(3): 774–815.
    CrossRefPubMed
  54. Huys QJm, Pizzagalli DA, Bogdan R, et al. Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis. Biol Mood Anxiety Disord. 2013; 3(1): 12.
    CrossRefPubMed
  55. Wu C, Lu J, Lu S, et al. Increased ratio of mature BDNF to precursor-BDNF in patients with major depressive disorder with severe anhedonia. J Psychiatr Res. 2020; 126: 92–97.
    CrossRefPubMed
  56. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006; 311(5762): 864–868.
    CrossRefPubMed
  57. Tu WJ, Qiu HC, Liu Q, et al. Decreased level of irisin, a skeletal muscle cell-derived myokine, is associated with post-stroke depression in the ischemic stroke population. J Neuroinflammation. 2018; 15(1): 133.
    CrossRefPubMed
  58. Szilasi ME, Pak K, Kardos L, et al. The Alteration of Irisin-Brain-Derived Neurotrophic Factor Axis Parallels Severity of Distress Disorder in Bronchial Asthma Patients. Front Neurosci. 2017; 11: 653.
    CrossRefPubMed
  59. Wang S, Pan J. Irisin ameliorates depressive-like behaviors in rats by regulating energy metabolism. Biochem Biophys Res Commun. 2016; 474(1): 22–28.
    CrossRefPubMed
  60. Altar CA, Laeng P, Jurata LW, et al. Neurotrophins and depression. Trends Pharmacol Sci. 1999; 20(2): 59–61.
    CrossRefPubMed
  61. Hou Z, Zhang J, Yu Ke, et al. Irisin ameliorates the postoperative depressive-like behavior by reducing the surface expression of epidermal growth factor receptor in mice. Neurochem Int. 2020; 135: 104705.
    CrossRefPubMed
  62. Normanno N, De Luca A, Bianco C, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005; 6(3): 243–257.
    CrossRefPubMed
  63. Austin S, St-Pierre J. PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012; 125(Pt 21): 4963–4971.
    CrossRefPubMed
  64. Siteneski A, Cunha MP, Lieberknecht V, et al. Central irisin administration affords antidepressant-like effect and modulates neuroplasticity-related genes in the hippocampus and prefrontal cortex of mice. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A): 294–303.
    CrossRefPubMed
  65. Ignácio ZM, da Silva RS, Plissari ME, et al. Physical Exercise and Neuroinflammation in Major Depressive Disorder. Mol Neurobiol. 2019; 56(12): 8323–8335.
    CrossRefPubMed
  66. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007; 69(7): 587–596.
    CrossRefPubMed
  67. Olson RL, Brush CJ, Ehmann PJ, et al. A randomized trial of aerobic exercise on cognitive control in major depression. Clin Neurophysiol. 2017; 128(6): 903–913.
    CrossRefPubMed
  68. Gourgouvelis J, Yielder P, Murphy B. Exercise Promotes Neuroplasticity in Both Healthy and Depressed Brains: An fMRI Pilot Study. Neural Plast. 2017; 2017: 8305287.
    CrossRefPubMed
  69. Phillips C, Fahimi A. Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression. Front Neurosci. 2018; 12: 498.
    CrossRefPubMed
  70. Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019; 102: 56–84.
    CrossRefPubMed
  71. Siteneski A, Olescowicz G, Pazini FL, et al. Antidepressant-like and pro-neurogenic effects of physical exercise: the putative role of FNDC5/irisin pathway. J Neural Transm (Vienna). 2020; 127(3): 355–370.
    CrossRefPubMed
  72. Kheirbek MA, Hen R. Dorsal vs ventral hippocampal neurogenesis: implications for cognition and mood. Neuropsychopharmacology. 2011; 36(1): 373–374.
    CrossRefPubMed
  73. Carpenter KM, Hasin DS, Allison DB, et al. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health. 2000; 90(2): 251–257.
    CrossRefPubMed
  74. Faith MS, Matz PE, Jorge MA. Obesity-depression associations in the population. J Psychosom Res. 2002; 53(4): 935–942.
    CrossRefPubMed
  75. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007; 62(4): 321–326.
    CrossRefPubMed
  76. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2003; 158(12): 1139–1147.
    CrossRefPubMed
  77. Blaine B. Does depression cause obesity?: A meta-analysis of longitudinal studies of depression and weight control. J Health Psychol. 2008; 13(8): 1190–1197.
    CrossRefPubMed
  78. de Wit L, Luppino F, van Straten A, et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010; 178(2): 230–235.
    CrossRefPubMed
  79. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010; 67(3): 220–229.
    CrossRefPubMed
  80. Hou N, Han F, Sun X. The relationship between circulating irisin levels and endothelial function in lean and obese subjects. Clin Endocrinol (Oxf). 2015; 83(3): 339–343.
    CrossRefPubMed
  81. Timmons JA, Baar K, Davidsen PK, et al. Is irisin a human exercise gene? Nature. 2012; 488(7413): E9–10; discussion E10.
    CrossRefPubMed
  82. Knol MJ, Twisk JWR, Beekman ATF, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006; 49(5): 837–845.
    CrossRefPubMed
  83. Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008; 31(12): 2383–2390.
    CrossRefPubMed
  84. Nefs G, Pouwer F, Denollet J, et al. The course of depressive symptoms in primary care patients with type 2 diabetes: results from the Diabetes, Depression, Type D Personality Zuidoost-Brabant (DiaDDZoB) Study. Diabetologia. 2012; 55(3): 608–616.
    CrossRefPubMed
  85. Duran ID, Gülçelik NE, Ünal M, et al. Irisin levels in the progression of diabetes in sedentary women. Clin Biochem. 2015; 48(18): 1268–1272.
    CrossRefPubMed
  86. Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm Metab Res. 2016; 48(10): 644–652.
    CrossRefPubMed
  87. Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27(4): 365–369.
    CrossRefPubMed
  88. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One. 2014; 9(4): e94235.
    CrossRefPubMed
  89. Lin H, Yuan Y, Tian S, et al. In Addition to Poor Glycemic Control, a High Level of Irisin in the Plasma Portends Early Cognitive Deficits Clinically in Chinese Patients With Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne). 2019; 10: 634.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl